Compare DexCom, Inc. (DXCM) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco Ltd. — how do they compare? DexCom, Inc. trades at $77.35 (market cap $28.06B), while Invesco Ltd. trades at $30.45 (market cap $13.43B). The key difference: DexCom, Inc. is far larger — about 2.1× Invesco Ltd.'s market cap, and Invesco Ltd. pays a 2.84% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | IVZ | |
|---|---|---|
Market Cap | $28.06B | $13.43B |
Sector | Health | Financials |
52-Week High | $89.53 | $30.30 |
52-Week Low | $54.84 | $16.88 |
Enterprise Value | $27.03B | $23.68B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Invesco (IVZ) trades at $30.50, up 6.16% in the past 24 hours, with a bullish technical signal from moving averages. The company reported mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $6.38 billion in 2025, though net income remained negative at -$281.70 million. Analyst consensus is divided with 12 buys and 16 holds, targeting $30.50 on average. Recent news highlights dividend declarations and AUM growth to $2.47 trillion as of June 2026.
The outlook for IVZ is cautiously optimistic, supported by strong cash flow from operations and upward earnings revisions. Key risks include persistent negative profit margins and competitive pressures in asset management. Upside potential hinges on execution improvements and market sentiment shifts, with the current price near the consensus target suggesting limited near-term movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
